Two of the most noteworthy developments in the oncology field during 2016 were the continued expansion of checkpoint blockade immunotherapy agents into more cancer types and the federal government’s plans for funding and remaking the research paradigm.
Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.
In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
To great fanfare, Hackensack Meridian Health of New Jersey and Memorial Sloan Kettering Cancer Center announced a co-branding partnership that they say would lead to highly fruitful collaborative research and make hundreds of clinical trial opportunities available to their patients.
President Barack Obama signed the 21st Century Cures Act into law today, earmarking $6.3 billion over 10 years for advancements in precision medicine development, brain research, heroin and prescription drug abuse prevention, and mental health.
Viewed by some as a boon for precision medicine, an Alzheimer’s cure, brain research, and opioid abuse prevention, but also seen as weakening the FDA’s regulatory power, the $6.3 billion 21st Century Cures Act passed overwhelmingly in the House Wednesday by a vote of 392-26.
While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.
Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.